Agios Pharmaceuticals, Inc.
AQVESME
thalassemia
Resolved
160days ago
Catalyst readout · Jan 28, 2026
What's at stake
A key catalyst for AQVESME (thalassemia) is expected Jan 28, 2026.
Primary source
· SEC 8-K
verified 16h ago
“AQVESME is expected to become available in the U.S. in late January 2026 following implementation of the AQVESME Risk Evaluation and Mitigation Strategy (REMS) program.”